Prevention of COPD exacerbation by lysozyme: a double-blind, randomized, placebo-controlled study

about

Pharmacological strategies to reduce exacerbation risk in COPD: a narrative review Understanding low COPD exacerbation rates in Japan: a review and comparison with other countries

P2860

Q28070274-23B31292-2267-442D-9639-CED3D1D52579 Q59126241-DC1B7BBB-FA08-490A-A319-E97010AD3E02

P2860

Prevention of COPD exacerbation by lysozyme: a double-blind, randomized, placebo-controlled study

Item

http://www.wikidata.org/entity/Q36838758

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Prevention of COPD exacerbatio ...... ized, placebo-controlled study

@en

type

Item

label

Prevention of COPD exacerbatio ...... ized, placebo-controlled study

@en

prefLabel

Prevention of COPD exacerbatio ...... ized, placebo-controlled study

@en

P1476

Prevention of COPD exacerbatio ...... ized, placebo-controlled study

@en

P2093

Hideaki Miyagishi

http://www.w3.org/2001/XMLSchema#string

Hiromasa Inoue

http://www.w3.org/2001/XMLSchema#string

Kai Shibata

http://www.w3.org/2001/XMLSchema#string

Koichiro Tatsumi

http://www.w3.org/2001/XMLSchema#string

Masakazu Ichinose

http://www.w3.org/2001/XMLSchema#string

Yasuhiro Marukawa

http://www.w3.org/2001/XMLSchema#string

Yoshinosuke Fukuchi

http://www.w3.org/2001/XMLSchema#string

Yukinori Sakata

http://www.w3.org/2001/XMLSchema#string

P2860

A review of the most common patient-reported outcomes in COPD--revisiting current knowledge and estimating future challenges

The nature of small-airway obstruction in chronic obstructive pulmonary disease

Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease.

Killing of gram-negative bacteria by lactoferrin and lysozyme

The path to personalised medicine in COPD.

An Official American Thoracic Society/European Respiratory Society Statement: Research questions in chronic obstructive pulmonary disease.

Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial.

Modulation of neutrophil function by lysozyme. Potential negative feedback system of inflammation.

Lysozyme secretion by submucosal glands protects the airway from bacterial infection.

Effects of salmeterol on cilia and mucus in COPD and pneumonia patients.

P304

831-838

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/COPD.S103105

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-04-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27143873

http://www.w3.org/2001/XMLSchema#string

P921

placebo

P932

4846053

http://www.w3.org/2001/XMLSchema#string

Prevention of COPD exacerbation by lysozyme: a double-blind, randomized, placebo-controlled study

about

P2860

P2860

Prevention of COPD exacerbation by lysozyme: a double-blind, randomized, placebo-controlled study

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P478

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P478

P577

P698

P921

P932